Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer Inc, 235 East 42nd Street, New York, New York 10017
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
A multi-center, open-label study of CP-690,550 in subjects with moderate to severe ulcerative colitis
To assess the safety and tolerability of long-term tofacitinib therapy in subjects with UC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017, USA
MAJ Il y a 4 ans
A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis
To demonstrate the efficacy of tofacitinib in inducing remission in subjects with moderately to severely active UC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis
To demonstrate the efficacy of CP 690,550 in inducing remission in subjects with moderately to severely active ulcerative colitis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis
To demonstrate the efficacy of tofacitinib as maintenance therapy in subjects with UC.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
Persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children
Immunogenicity Persistence At 2, 3, 4, 5, 6 years after booster vaccination of children with MenACWY-TT or Meningitec •To evaluate the persistence of meningococcal antibodies in terms of the perce...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc, 235 East 42nd Street, New York, New York 10017
MAJ Il y a 4 ans
To evaluate the safety and immunogenicity of a booster dose of meningococcal vaccine administered 10 years after primary vaccination of 1-10 year old subjects with MenACWY-TT (PF-06866681), Meningitec or Mencevax ACWY
•To evaluate the long-term persistence of the serum bactericidal (antibody) titres induced by MenACWY-TT vaccine as compared to Meningitec when administered to individuals 1-<2 years of age in terms o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations